BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions

Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?

(2020) Patrick Schummer et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

ERK/MAPK signalling pathway and tumorigenesis (Review)

(2020) Yan‑Jun Guo et al.   Experimental and Therapeutic Medicine

Current Advances in the Treatment of BRAF-Mutant Melanoma

(2020) Hima Patel et al.   Cancers

Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy

(2020) Nalan Akgul Babacan et al.   Current Oncology Reports

Targeting the ERK Signaling Pathway in Melanoma

(2019) Paola Savoia et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) Daniel G. Coit et al.   Journal of the National Comprehensive Cancer Network

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma

(2019) Jason J. Luke   ONCOLOGIST

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

(2019) Chune Yu et al.   Frontiers in Immunology

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside

(2019) Taku Fujimura et al.   Cancers

Management of V600E and V600K BRAF-Mutant Melanoma

(2019) Alexandra M. Haugh et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Considering adjuvant therapy for stage II melanoma

(2019) Andrew S. Poklepovic et al.   CANCER

Principles of Targeted Therapy for Melanoma

(2019) James Sun et al.   SURGICAL CLINICS OF NORTH AMERICA

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

(2019) Dan A. Erkes et al.   Cancer Discovery

Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review

(2019) Austin Greco et al.   Cancers

Development of encorafenib for BRAF-mutated advanced melanoma

(2018) Peter Koelblinger et al.   CURRENT OPINION IN ONCOLOGY

Cutaneous melanoma: From pathogenesis to therapy (Review)

(2018) Giulia Leonardi et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy

(2018) Marvin Kuske et al.   PHARMACOLOGICAL RESEARCH

BRAF inhibitors: resistance and the promise of combination treatments for melanoma

(2017) Merope Griffin et al.   Oncotarget

Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma

(2017) Hassan Sadozai et al.   Frontiers in Immunology

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma

(2016) Alex Kim et al.   Expert Opinion on Drug Discovery

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells

(2016) Chery A. Whipple et al.   MELANOMA RESEARCH

Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity

(2016) Charles H. Adelmann et al.   Oncotarget

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

(2016) Marcel A. Deken et al.   OncoImmunology

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

(2015) S. D. Bradley et al.   Cancer Immunology Research

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

(2015) Blanca Homet Moreno et al.   OncoImmunology

Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFN 

(2014) P.-C. Ho et al.   CANCER RESEARCH

Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment

(2014) J. S. Wilmott et al.   JOURNAL OF IMMUNOLOGY

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology, Risk Factors, Prevention, and Early Detection of Melanoma

(2014) Saïd C. Azoury et al.   SURGICAL CLINICS OF NORTH AMERICA

BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma

(2014) S. M. Steinberg et al.   Cancer Immunology Research

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

(2014) Z. A. Cooper et al.   Cancer Immunology Research

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma

(2014) Zachary A Cooper et al.   OncoImmunology

Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations

(2013) Giusy Gentilcore et al.   BMC CANCER

Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties

(2013) Patrick A. Ott et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

(2013) Deborah A. Knight et al.   JOURNAL OF CLINICAL INVESTIGATION

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

(2013) Alastair J. King et al.   PLoS One

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

(2013) Tara R. Rheault et al.   ACS Medicinal Chemistry Letters

Immunological consequences of selective BRAF inhibitors in malignant melanoma

(2013) Bastian Schilling et al.   OncoImmunology

Melanoma incidence and mortality in Europe: new estimates, persistent disparities

(2012) A.M. Forsea et al.   BRITISH JOURNAL OF DERMATOLOGY

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

(2012) C. Liu et al.   CLINICAL CANCER RESEARCH

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutant BRAF Melanomas—Dependence and Resistance

(2011) Poulikos I. Poulikakos et al.   CANCER CELL

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

(2010) H. Yang et al.   CANCER RESEARCH

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA